Positron emission tomography (PET) uses radioactive tracers and enables the functional
imaging of several metabolic processes, blood flow measurements, regional chemical …

Immuno-positron emission tomography (immunoPET) is a paradigm-shifting molecular
imaging modality combining the superior targeting specificity of monoclonal antibody (mAb) …

Targeted anticancer drugs block cancer cell growth by interfering with specific signaling
pathways vital to carcinogenesis and tumor growth rather than harming all rapidly dividing …

Antibodies targeting the PD-1/PD-L1 immune checkpoint lead to tumor regression and
improved survival in several cancers. PD-L1 expression in tumors may be predictive of …

89Zr is an emerging radionuclide that plays an essential role in immuno-positron emission
tomography (PET) imaging. The long half-life of 89Zr (t1/2= 3.3 days) is favorable for …

Owing to improvements in our understanding of the biological principles of tumour initiation
and progression, a wide variety of novel targeted therapies have been developed …

Selection of the right drug for the right patient is a promising approach to increase clinical
benefit of targeted therapy with monoclonal antibodies (mAbs). Assessment of in vivo …

Immuno-positron emission tomography (immunoPET) is a molecular imaging modality
combining the high sensitivity of PET with the specific targeting ability of monoclonal …

The identification of molecular drivers of disease and the compelling rise of biotherapeutics
have impacted clinical care but have also come with challenges. Such therapeutics include …

In theranostics, radiolabeled compounds are used to determine a treatment strategy by
combining therapeutics and diagnostics in the same agent. Monoclonal antibodies (mAbs) …